Fortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Fortress Biotech

13/08/2026 21:56

Fortress Biotech Inc FBIO.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -50 cents.  The lone analyst forecast for the quarter was for a loss of 20 cents per share. 
Revenue rose 14% to $18.72 million from a year ago; analysts expected $18.30 million. 
Fortress Biotech Inc's reported EPS for the quarter was a loss of 8 cents​.
The company reported a quarterly loss of $2.48 million.
Fortress Biotech Inc shares had fallen by 10.1% this quarter and lost 24.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 5.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Fortress Biotech Inc is $11.00, about 75% above its last closing price of $2.75
This summary was machine generated from LSEG data August 13 at 08:56 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.20
-0.08
Beat
Mar. 31 2026 
-0.22
-1.13
Missed
Dec. 31 2025 
0.11
-0.01
Missed
Sep. 30 2025 
-0.42
0.11
Beat